Compare State Street SPDR S&P Biotech ETF (XBI) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR S&P Biotech ETF vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? State Street SPDR S&P Biotech ETF trades at $159.61, while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.19. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| XBI | YMAG | |
|---|---|---|
Sector | Broad Market / Factor | Income / Options Overlay |
52-Week High | $169.55 | $15.98 |
52-Week Low | $93.43 | $10.76 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XBI (SPDR S&P Biotech ETF) trades at $161.97, down 1.12% on the day, with a bearish technical signal overall despite bullish moving averages. The ETF holds over 150 biotech companies, benefiting from strong M&A activity and positive clinical catalysts, though key financial ratios are not applicable for the fund structure. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic given sector tailwinds, but high volatility and concentration in small-cap biotech pose risks. The single analyst covering the ETF maintains a Hold rating, reflecting a neutral stance amid the sector's rally and inherent volatility.
YMAG trades at $11.26, down 0.18% with a bullish technical signal supported by moving averages. The ETF maintains consistent weekly dividend distributions, though key valuation metrics remain unavailable. Recent trading activity shows moderate volume with price stability around the $11 support level.
The outlook remains cautiously optimistic given the bullish technical setup and income generation, but lack of fundamental data creates uncertainty. Investors face risks from NAV volatility during earnings periods and dependency on option income strategies for distributions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
